Pfizer and BioNTech begin Phase I trials of an mRNA-based combination vaccine to protect against influenza and COVID-19. The vaccine dose was already given to the first participant in the US. The study is to assess the safety, tolerability and immunogenicity of the preparation.
The vaccine candidate combines Pfizer's mRNA-based quadrivalent influenza vaccine, currently in Phase III clinical trials, and a bivalent COVID-19 vaccine to p...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
